Sage Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2013 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Sage Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2013 to Q3 2024.
  • Sage Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$93.6M, a 53.6% increase year-over-year.
  • Sage Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$338M, a 48.5% increase year-over-year.
  • Sage Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$541M, a 1.63% decline from 2022.
  • Sage Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$533M, a 16.4% decline from 2021.
  • Sage Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$458M, a 176% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$338M -$93.6M +$108M +53.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-29
Q2 2024 -$446M -$103M +$57.5M +35.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-10-29
Q1 2024 -$503M -$108M +$38.3M +26.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-10-29
Q4 2023 -$541M -$32.7M +$114M +77.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-14
Q3 2023 -$656M -$202M -$64.3M -46.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-29
Q2 2023 -$592M -$160M -$34.1M -27% Apr 1, 2023 Jun 30, 2023 10-Q 2024-10-29
Q1 2023 -$558M -$147M -$24.8M -20.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-10-29
Q4 2022 -$533M -$147M -$22.4M -18% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-14
Q3 2022 -$510M -$137M -$7.15M -5.49% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$503M -$126M -$19M -17.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-07
Q1 2022 -$484M -$122M -$26.3M -27.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-07
Q4 2021 -$458M -$125M -$1.1B -113% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-14
Q3 2021 $642M -$130M -$24.4M -23.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $666M -$107M +$29.1M +21.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 $637M -$95.8M +$31M +24.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08
Q4 2020 $606M $975M +$1.14B Oct 1, 2020 Dec 31, 2020 10-K 2021-02-24
Q3 2020 -$537M -$106M +$74.2M +41.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 -$612M -$136M +$31.9M +18.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-02
Q1 2020 -$644M -$127M +$36.7M +22.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-02
Q4 2019 -$680M -$169M -$10.3M -6.48% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-24
Q3 2019 -$670M -$180M -$57M -46.4% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-24
Q2 2019 -$613M -$168M -$151M -891% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-24
Q1 2019 -$462M -$163M -$88.8M -119% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-24
Q4 2018 -$373M -$158M -$89M -128% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$284M -$123M -$49.2M -66.7% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 -$235M -$17M +$53.2M +75.8% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 -$288M -$74.6M -$17.8M -31.4% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
Q4 2017 -$270M -$69.4M -$13.5M -24.2% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-19
Q3 2017 -$257M -$73.7M -$35.9M -95% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-19
Q2 2017 -$221M -$70.2M -$35.5M -102% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-19
Q1 2017 -$185M -$56.8M -$26.2M -85.9% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-19
Q4 2016 -$159M -$55.9M -$27.3M -95.7% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-22
Q3 2016 -$132M -$37.8M -$13.8M -57.3% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-22
Q2 2016 -$118M -$34.7M -$9.72M -38.8% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-22
Q1 2016 -$108M -$30.5M -$13.7M -81% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-22
Q4 2015 -$94.5M -$28.6M -$16.2M -131% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-24
Q3 2015 -$78.3M -$24M -$14.6M -154% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-24
Q2 2015 -$63.7M -$25M -$18.8M -304% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-24
Q1 2015 -$44.9M -$16.9M -$11.1M -191% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-24
Q4 2014 -$33.8M -$12.4M Oct 1, 2014 Dec 31, 2014 10-K 2016-02-29
Q3 2014 -$9.47M -$4.95M -110% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-29
Q2 2014 -$6.19M -$1.54M -33% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-29
Q1 2014 -$5.79M Jan 1, 2014 Mar 31, 2014 10-K 2016-02-29
Q3 2013 -$4.52M Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-13
Q2 2013 -$4.66M Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.